MetaVia Inc.
MTVA
Pozycja w akcjach
#32875
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Cena akcji
$1.30
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$8.53M
Zmiana (1 dzień)
-5.47%
Zmiana (1 rok)
-20.55%
Kraj
US
Handel MetaVia Inc. (MTVA)
Kategoria
Healthcare
Kapitalizacja rynkowa MetaVia Inc.(MTVA)
Kapitalizacja rynkowa: $8.53M
Na dzień October 2026 spółka MetaVia Inc. ma kapitalizację rynkową wynoszącą $8.53M. Według naszych danych, czyni to MetaVia Inc. 32875th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej MetaVia Inc. od 2016 do 2026
MTVA w porównaniu do 5 najpopularniejszych stocks
